2011-04-22 – Page 2 – China Stock Advice

IDI [IDI] 6-K: (Original Filing)

[April 22, 2011 LLP LLP Bernstein & Pinchuk] [SearchMedia Confirms Form 6-K Required due to Bernstein & Pinchuk LLPs Joint Venture with Marcum LLP B&P had been engaged by the Company to audit its financial statements since May 2010 and provided its audit report for the Companys financial statements for the years ended December 31, 2009 and December 31, 2008. During these fiscal years and the subsequent interim] [FORM 6-K April 18, 2011 SearchMedia Holdings Limited Cayman Islands (Jurisdiction of incorporation or organization) 13F Central Modern Building x x n/a SearchMedia Holdings Limited Paul Conway Paul Conway Cheif Executive Officer Description 16.1 Letter to the SEC from Bernstein & Pinchuk dated April 22, 2011]

By info| 2016-03-19T16:11:09+00:00 April 22nd, 2011|Categories: Chinese Stocks, IDI, SEC Original|Tags: 0001460329, 2011-04-22, 6-K, 7310, IDI, SERVICES-ADVERTISING|0 Comments

IDI [IDI] 6-K: April 22, 2011 LLP LLP Bernstein & Pinchuk

[April 22, 2011 LLP LLP Bernstein & Pinchuk] [SearchMedia Confirms Form 6-K Required due to Bernstein & Pinchuk LLPs Joint Venture with Marcum LLP B&P had been engaged by the Company to audit its financial statements since May 2010 and provided its audit report for the Companys financial statements for the years ended December 31, 2009 and December 31, 2008. During these fiscal years and the subsequent interim] [FORM 6-K April 18, 2011 SearchMedia Holdings Limited Cayman Islands (Jurisdiction of incorporation or organization) 13F Central Modern Building x x n/a SearchMedia Holdings Limited Paul Conway Paul Conway Cheif Executive Officer Description 16.1 Letter to the SEC from Bernstein & Pinchuk dated April 22, 2011]

By info| 2016-03-19T16:12:25+00:00 April 22nd, 2011|Categories: Chinese Stocks, IDI, Webplus ver|Tags: 0001460329, 2011-04-22, 6-K, 7310, IDI, SERVICES-ADVERTISING|0 Comments

SVA [SINOVAC BIOTECH] 20-F: (Original Filing)

[Indicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by the annual report. 54,305,961 common shares as of December 31, 2010 o x o x x o o o] [List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Tangshan Yian Biological Engineering Co., Ltd., a PRC company 3. Sinovac Biotech Co., Ltd., a PRC company 4. Sinovac Research and Development Co., Ltd. (formerly known as Beijing Sinovac Biological Technology Co., Ltd.), a PRC company 5. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company] [Certification by the Chief Executive Officer I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [Certification by the Chief Financial Officer I, Jacob Chik Keung Ho, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in] [Certification by the Chief Executive Officer 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. EX-13.1 13 v219311_ex13-1.htm] [Certification by the Chief Financial Officer 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. EX-13.2 14 v219311_ex13-2.htm] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement (Form S−8 No. 333−161827) pertaining to the 2003 Stock Option Plan of Sinovac Biotech Ltd., of our reports dated April 22, 2011, with respect to the consolidated financial statements of Sinovac Biotech Ltd., and the effectiveness of internal control over financial reporting]

By info| 2016-03-24T02:00:43+00:00 April 22nd, 2011|Categories: Chinese Stocks, SEC Original, SVA|Tags: 0001084201, 20-F, 2011-04-22, 2834, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments

SVA [SINOVAC BIOTECH] 20-F: Indicate the number of outstanding shares of each

[Indicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by the annual report. 54,305,961 common shares as of December 31, 2010 o x o x x o o o] [List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Tangshan Yian Biological Engineering Co., Ltd., a PRC company 3. Sinovac Biotech Co., Ltd., a PRC company 4. Sinovac Research and Development Co., Ltd. (formerly known as Beijing Sinovac Biological Technology Co., Ltd.), a PRC company 5. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company] [Certification by the Chief Executive Officer I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [Certification by the Chief Financial Officer I, Jacob Chik Keung Ho, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in] [Certification by the Chief Executive Officer 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. EX-13.1 13 v219311_ex13-1.htm] [Certification by the Chief Financial Officer 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. EX-13.2 14 v219311_ex13-2.htm] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement (Form S−8 No. 333−161827) pertaining to the 2003 Stock Option Plan of Sinovac Biotech Ltd., of our reports dated April 22, 2011, with respect to the consolidated financial statements of Sinovac Biotech Ltd., and the effectiveness of internal control over financial reporting]

By info| 2016-03-24T02:02:42+00:00 April 22nd, 2011|Categories: Chinese Stocks, SVA, Webplus ver|Tags: 0001084201, 20-F, 2011-04-22, 2834, PHARMACEUTICAL PREPARATIONS, SVA|0 Comments